图卡替尼对比安慰剂联合曲妥珠单抗和卡培他滨治疗经治HER2阳性转移性乳腺癌伴或不伴脑转移患者(HER2CLIMB):最终总生存分析
HER2CLIMB是一项随机双盲安慰剂对照试验,共纳入612例局部晚期或转移性HER2阳性乳腺癌患者(含脑转移)。在中位总生存随访29.6个月时,图卡替尼联合组中位总生存为24.7个月,安慰剂联合组为19.2个月(HR 0.73,95%CI 0.59-0.90,P=0.004)。图卡替尼联合组耐受性良好,因不良事件停药率低。
要点
- 图卡替尼联合组中位总生存24.7个月,安慰剂联合组19.2个月(HR 0.73,95%CI 0.59-0.90,P=0.004)。
- 图卡替尼联合组2年总生存率为51%,安慰剂联合组为40%。
- 图卡替尼联合组中位无进展生存期为7.6个月,安慰剂联合组为4.9个月(HR 0.57,95%CI 0.47-0.70,P<0.00001)。
核心结论
- 随着随访时间延长,图卡替尼联合方案为HER2阳性转移性乳腺癌患者提供了具有临床意义的生存获益。
研究设计与样本
- HER2CLIMB是一项随机、双盲、安慰剂对照试验,纳入局部晚期或转移性HER2阳性乳腺癌患者,包括脑转移患者。
- 患者按2:1随机接受图卡替尼或安慰剂,联合曲妥珠单抗和卡培他滨治疗。
- 共612例患者入组HER2CLIMB试验。
- 主要分析(中位随访14个月)后,方案修订允许研究中心揭盲治疗分配,并允许从安慰剂联合组交叉至图卡替尼联合组。
- 在末例患者随机化后约2年时,按方案预设进行总生存、无进展生存(研究者评估)和安全性的描述性分析。
主要发现
- 在中位总生存随访29.6个月时,图卡替尼联合组中位总生存为24.7个月,安慰剂联合组为19.2个月(死亡HR 0.73,95%CI 0.59-0.90,P=0.004)。
- 图卡替尼联合组2年总生存率为51%,安慰剂联合组为40%。
- 预设亚组的总生存HR与总体研究人群的HR一致。
- 图卡替尼联合组中位无进展生存期为7.6个月,安慰剂联合组为4.9个月(进展或死亡HR 0.57,95%CI 0.47-0.70,P<0.00001)。
- 图卡替尼联合组1年无进展生存率为29%,安慰剂联合组为14%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. We report efficacy and safety outcomes, including the final OS and safety outcomes from follow-up in HER2CLIMB. PATIENTS AND METHODS: HER2CLIMB is a randomized, double-blind, placebo-controlled trial in patients with locally advanced or metastatic HER2+ breast cancer, including patients with brain metastases. Patients were randomized 2 : 1 to receive tucatinib or placebo, in combination with trastuzumab and capecitabine. After the primary analysis (median follow-up of 14 months), the protocol was amended to allow for unblinding sites to treatment assignment and cross-over from the placebo combination to the tucatinib combination. Protocol prespecified descriptive analyses of OS, PFS (by investigator assessment), and safety were carried out at ∼2 years from the last patient randomized. RESULTS: Six hundred and twelve patients enrolled in the HER2CLIMB trial. At a median OS follow-up of 29.6 months, median duration of OS was 24.7 months for the tucatinib combination group versus 19.2 months for the placebo combination group [hazard ratio (HR) for death: 0.73, 95% confidence interval (CI): 0.59-0.90, P = 0.004] and OS at 2 years was 51% and 40%, respectively. HRs for OS across prespecified subgroups were consistent with the HR for the overall study population. Median duration of PFS was 7.6 months for the tucatinib combination group versus 4.9 months for the placebo combination group (HR for progression or death: 0.57, 95% CI: 0.47-0.70, P < 0.00001) and PFS at 1 year was 29% and 14%, respectively. The tucatinib combination was well tolerated with a low rate of discontinuation due to adverse events. CONCLUSIONS: With additional follow-up, the tucatinib combination provided a clinically meaningful survival benefit for patients with HER2+ metastatic breast cancer.
引用
- Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2021. PMID: 34954044. doi:10.1016/j.annonc.2021.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。